Snowflake surged 24 % after posting second-quarter results that beat expectations, with adjusted earnings of 62 cents per share on revenue of $1.55 billion. Chipmaker Broadcom fell 2.5 % as its fourth-quarter revenue forecast came in below estimates. Ultragenyx Pharmaceutical collapsed more than 46 % after Phase 3 trial results for its Angelman syndrome drug failed to achieve its primary endpoint. Meanwhile, Victoria’s Secret sank more than 18 % following slightly missed revenue estimates in its second-quarter results.
Source: Read the original article
